Syndax Pharmaceuticals (SNDX) Equity Average (2016 - 2026)

Syndax Pharmaceuticals' Equity Average history runs 11 years deep, the most recent figure standing at $53.1 million for Q1 2026.

• In Q1 2026, Equity Average fell 78.88% year-over-year to $53.1 million; the TTM figure through Mar 2026 stood at $53.1 million (down 78.88% YoY), while the FY2025 annual figure was $176.4 million, down 58.12% from the prior year.
• Equity Average was $53.1 million for Q1 2026 at Syndax Pharmaceuticals, down from $90.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $523.0 million in Q1 2024 to a low of $53.1 million in Q1 2026.
• Historically, Equity Average has averaged $332.3 million across 5 years, with a median of $379.6 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Equity Average jumped 69.27% in 2022, then tumbled 78.88% in 2026.
• A 5-year view of Equity Average shows it stood at $402.8 million in 2022, then grew by 13.39% to $456.7 million in 2023, then decreased by 28.34% to $327.3 million in 2024, then slumped by 72.49% to $90.0 million in 2025, then tumbled by 40.99% to $53.1 million in 2026.
• The last three Equity Average figures came in at $53.1 million (Q1 2026), $90.0 million (Q4 2025), and $136.4 million (Q3 2025), per Business Quant data.